Payment overview · 2025
General Payments
$392.39
22 reported records · 19 companies
Healthcare provider profile · identity verified
William Hugh Nesbit, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TULSA, OK · NPI 1083887798
Verified facts
What the public records show
CMS Open Payments records show William Hugh Nesbit, M.D. received $392.39 in general payments during 2025 across 22 reported records.
Axsome Therapeutics, Inc. accounted for 9.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cuvitru by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.20 | 9.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $37.46 | 9.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.32 | 7.7% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $22.39 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.00 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 5.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.70 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.26 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.29 | 4.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.08 | 4.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.98 | 4.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.22 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.89 | 4.3% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $15.61 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.01 | 3.8% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $14.79 | 3.8% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.41 | 3.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.16 | 3.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.14 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $392.39 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 198 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 173 | 55 |
| Metformin Hcl Er | Metformin Hcl | 165 | 58 |
| Lisinopril | Lisinopril | 163 | 49 |
| Omeprazole | Omeprazole | 155 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 41 |
| Gabapentin | Gabapentin | 107 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 33 |
| Carvedilol | Carvedilol | 98 | 29 |
| Ezetimibe | Ezetimibe | 94 | 38 |
| Potassium Chloride | Potassium Chloride | 91 | 35 |
| Diazepam | Diazepam | 89 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 88 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 27 |
| Furosemide | Furosemide | 83 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 25 |
| Losartan Potassium | Losartan Potassium | 78 | 27 |
| Ozempic | Semaglutide | 78 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 23 |
| Trazodone Hcl | Trazodone Hcl | 68 | 23 |
| Memantine Hcl | Memantine Hcl | 67 | 23 |
| Methocarbamol | Methocarbamol | 58 | 26 |
| Celecoxib | Celecoxib | 56 | 20 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 54 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | suppressed |
| Baclofen | Baclofen | 53 | 20 |
| Alendronate Sodium | Alendronate Sodium | 51 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 41 | 16 |
| Buspirone Hcl | Buspirone Hcl | 40 | 13 |
| Doxepin Hcl | Doxepin Hcl | 40 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 14 |
| Montelukast Sodium | Montelukast Sodium | 38 | 15 |
| Metformin Hcl | Metformin Hcl | 37 | 12 |
| Morphine Sulfate | Morphine Sulfate | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Eliquis | Apixaban | 36 | 13 |
| Finasteride | Finasteride | 36 | 12 |
| Folic Acid | Folic Acid | 35 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Bupropion Xl | Bupropion Hcl | 31 | 11 |
| Prazosin Hcl | Prazosin Hcl | 31 | 13 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | 11 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 28 | suppressed |
| Calcitriol | Calcitriol | 27 | 11 |
| Jardiance | Empagliflozin | 27 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | 12 |
| Prednisone | Prednisone | 27 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nabumetone | Nabumetone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Prolia | Denosumab | 17 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $392.39 · 22 records | Axsome Therapeutics, Inc. | APRETUDE, Auvelity, BREZTRI, Belbuca, GEMTESA, JARDIANCE, JOURNAVX, KISUNLA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, QUTENZA, Qelbree, REPATHA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, WAKIX, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error